‘s stock had its “buy” rating reissued by research analysts at Citigroup Inc. in a research report issued on Saturday. They currently have a $88.00 price target on the biopharmaceutical company’s stock.
Category: JP Morgan Chase
ACADIA Pharmaceuticals Inc. (ACAD) Receives “Outperform” Rating from Cowen and Company
Cowen and Company currently has a $42.00 target price on the biopharmaceutical company’s stock. Several other equities analysts have also weighed in on the stock.